IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.57▲ 0.31% USD/CLP994.16▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN3.41▲ 0.18% USD/ARS1,544▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB11.59— 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.75▲ 2.58% EUR/BRL6.25▼ 0.04% BRENT 92.71 ▼ 3.27% WTI 88.47 ▼ 0.10% IRON ORE 161.91 — — COPPER 6.02 ▼ 0.90% GOLD 3,857 ▼ 0.75% SILVER 47.26 ▼ 3.62% SOY 1,228 ▼ 1.21% CORN 445.00 ▼ 0.11% WHEAT 591.00 ▼ 0.38% COFFEE 279.10 ▲ 0.16% SUGAR 18.30 ▼ 0.60% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,145 ▲ 0.51% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.58 ▲ 0.38% USD/CLP 994.16 ▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN 3.41 ▲ 0.17% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 ▲ 2.15% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.25 ▼ 0.04% BRENT 92.71 ▼ 3.27% WTI 88.47 ▼ 0.10% IRON ORE 161.91 — — COPPER 6.02 ▼ 0.90% GOLD 3,857 ▼ 0.75% SILVER 47.26 ▼ 3.62% SOY 1,228 ▼ 1.21% CORN 445.00 ▼ 0.11% WHEAT 591.00 ▼ 0.38% COFFEE 279.10 ▲ 0.16% SUGAR 18.30 ▼ 0.60% ORANGE JUICE 136.85 ▼ 2.91% COTTON 81.40 ▲ 3.33% COCOA 5,145 ▲ 0.51% BEEF 220.65 ▲ 0.80% CATTLE 339.03 ▲ 1.00% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Covid-19 Brazil

Brazil’s homegrown Butanvac trials to begin in June; 6 countries intend to import vaccine – state governor

By · · 3 min read

RIO DE JANEIRO, BRAZIL – São Paulo governor João Doria (PSDB) on Monday, June 14, said that clinical trials of the Butanvac vaccine, an immunizer against Covid-19 developed by the Butantan Institute, should begin by the end of June and that there are now 6 Latin American countries interested in its importation, should it be approved by the Brazilian Health Regulatory Agency (ANVISA) after trials are completed.

Last week, Brazil’s health regulator authorized the Butanvac clinical trials to begin. At this stage, the immunizer – which has undergone laboratory tests – will be administered to humans.

1
São Paulo governor João Doria.
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

According to Doria, trials should begin by the end of June, starting in the city of Ribeirão Preto, São Paulo, through the University of São Paulo (USP).

Butanvac is one of the vaccines being developed by Brazil. Other immunizers are also being tested in Brazilian federal universities, but they are struggling with budget shortages. Brazilian vaccines are an effort to tackle the potential need to revaccinate the entire Brazilian population against Covid-19 next year.

According to Doria, the three clinical trial phases should be completed in 120 days. After that, the data will be submitted to a new evaluation by ANVISA. There are now 7 million Butanvac vaccines produced and stocked. Another 18 million will be completed by July 31, according to the governor, and 40 million by October 30.

“As soon as ANVISA grants approval, São Paulo will be in a position to provide 40 million doses. Either to complete the vaccination schedule in Brazil, or for the vaccination of the new stage, the 2022 stage, when we will need vaccines again,” said Doria, after an event to launch a program to distribute pads in schools.

The governor also said that the Butanvac will be offered to bolster the National Immunization Plan (PNI) should the Ministry of Health so wish. “If it does not want to, São Paulo will use it in its own vaccination plan and will also export it. Six Latin American countries have already sent requests to Butantan. As soon as we secure approval, they are interested in the acquisition, targeting a new vaccination process next year.” Doria did not detail which 6 countries are interested in the immunizer.

According to the governor, “several states and cities” have also expressed interest in purchasing the Butanvac, should it prove effective. Among states, there are 8 interested. The Butanvac will cost R$10 (US$1.98) per dose, one-fourth of the price of the Coronavac, the immunizer developed by Chinese Sinovac pharmaceutical company in partnership with  Butantan.

Source: Estadão

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.